AstraZeneca PLC (AZN)vsIntercontinental Exchange Inc (ICE)
AZN
AstraZeneca PLC
$183.40
-2.00%
HEALTHCARE · Cap: $284.63B
ICE
Intercontinental Exchange Inc
$156.83
-0.55%
FINANCIAL SERVICES · Cap: $88.85B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 491% more annual revenue ($58.74B vs $9.93B). ICE leads profitability with a 33.4% profit margin vs 17.4%. AZN appears more attractively valued with a PEG of 1.50. AZN earns a higher WallStSmart Score of 66/100 (B-).
AZN
Strong Buy66
out of 100
Grade: B-
ICE
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+32.8%
Fair Value
$306.07
Current Price
$183.40
$122.67 discount
Margin of Safety
+38.6%
Fair Value
$255.26
Current Price
$156.83
$98.43 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 49.6%
Large-cap with strong market position
Earnings expanding 23.4% YoY
Generating 1.1B in free cash flow
Areas to Watch
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Expensive relative to growth rate
Moderate valuation
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : ICE
The strongest argument for ICE centers on Profit Margin, Operating Margin, Market Cap. Profitability is solid with margins at 33.4% and operating margin at 49.6%.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Revenue Growth, Altman Z-Score.
Bear Case : ICE
The primary concerns for ICE are PEG Ratio, P/E Ratio, Altman Z-Score.
Key Dynamics to Monitor
AZN profiles as a value stock while ICE is a mature play — different risk/reward profiles.
ICE carries more volatility with a beta of 1.05 — expect wider price swings.
ICE is growing revenue faster at 7.8% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (66/100 vs 63/100), backed by strong 17.4% margins. ICE offers better value entry with a 38.6% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Intercontinental Exchange Inc
FINANCIAL SERVICES · FINANCIAL DATA & STOCK EXCHANGES · USA
The Intercontinental Exchange (ICE) is an American Fortune 500 company formed in 2000 that operates global exchanges, clearing houses and provides mortgage technology, data and listing services. The company owns exchanges for financial and commodity markets, and operates regulated exchanges and marketplaces.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?